德展健康(000813) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥470,318,621.70, a decrease of 2.21% compared to ¥480,934,229.19 in the same period last year[9] - The net profit attributable to shareholders for Q1 2020 was ¥91,561,632.00, down 24.21% from ¥120,802,841.01 in the previous year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥73,029,190.26, a decline of 39.15% compared to ¥120,017,665.13 in the same period last year[9] - The basic earnings per share for Q1 2020 was ¥0.0413, down 24.22% from ¥0.0545 in the same period last year[9] - The diluted earnings per share for Q1 2020 was also ¥0.0413, reflecting a decrease of 24.22% compared to ¥0.0545 in the previous year[9] - The weighted average return on equity was 1.62%, down from 2.26% in the same period last year, a decrease of 0.64%[9] - The total comprehensive income for the current period is CNY 91,064,829.49, down from CNY 120,802,841.01 in the previous period[71] - The net profit for the current period is -11,571,500.94, compared to -4,781,453.42 in the previous period, indicating a significant increase in losses[75] - The total comprehensive income for the current period is -11,571,500.94, compared to -4,781,453.42 in the previous period, reflecting a worsening financial position[78] Cash Flow - The net cash flow from operating activities increased by 18.14% to ¥455,715,435.22 from ¥385,741,120.49 in the previous year[9] - Cash inflow from operating activities is 686,602,468.33, down from 951,154,755.35 in the previous period, showing a decline of approximately 27.8%[79] - The net cash flow from operating activities is 455,715,435.22, an increase from 385,741,120.49 in the previous period, representing a growth of about 18.1%[82] - The company reported a net cash flow from financing activities of CNY 0.00, down from a negative CNY 5.55 million in the previous period, primarily due to stock repurchases[24] - The net cash flow from investing activities is -948,338,137.51, worsening from -783,861,171.85 in the previous period[82] - The total cash outflow for operating activities is 230,887,033.11, significantly lower than 565,413,634.86 in the previous period, indicating improved cash management[82] - The net cash flow from financing activities was $24,664,890.41, a recovery from a negative cash flow of -$5,546,260.58 in the previous period[89] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,191,654,551.65, reflecting a growth of 4.45% from ¥5,927,795,521.33 at the end of the previous year[9] - The total assets amount to CNY 11,213,801,743.09, an increase from CNY 11,187,870,638.23 in the previous period[60] - Total liabilities increased to CNY 457,241,242.11 from CNY 316,152,923.63, marking a rise of approximately 44.6%[50] - The total liabilities amount to CNY 1,486,002,711.91, an increase from CNY 1,448,500,106.11 in the previous period[60] - The company's equity attributable to shareholders reached CNY 5,704,422,256.92, up from CNY 5,612,860,624.92, an increase of about 1.6%[52] - The company's equity attributable to shareholders was $5,612,860,624.92, remaining unchanged[97] Investments and Acquisitions - The company completed the acquisition of a 20% stake in Yunnan Suma Biotechnology Co., Ltd. for CNY 100 million, with the registration completed by December 31, 2019[25] - The company signed a framework agreement for the acquisition of 100% of Jincheng Pharmaceutical Co., Ltd. on September 25, 2019, with an initial agreement valid until November 4, 2019, later extended to January 4, 2020[26] - On March 23, 2020, the company signed an investment agreement to acquire 70% equity of Beijing Changjiang Mai Pharmaceutical Technology Co., Ltd. for RMB 770 million[29] - The company agreed to pay an investment intention fee of RMB 230 million to Dai Yanzhen for acquiring 51.6873% equity in Changjiang Mai Company, with a subsequent agreement to increase the prepayment to RMB 200 million[26] Research and Development - R&D expenses increased by 33.10% to CNY 15.57 million from CNY 11.70 million, reflecting increased investment in R&D projects[21] - Research and development expenses for the current period are CNY 15,569,693.37, up from CNY 11,697,601.46 in the previous period, marking an increase of approximately 33.3%[65] Other Financial Metrics - The company reported a government subsidy of ¥417,610.03 during the reporting period[9] - The company experienced a 539.99% increase in taxes payable, rising to CNY 32.83 million from CNY 5.13 million, mainly due to increased income tax payable[21] - The company reported an investment income of CNY 20.76 million, compared to CNY 0.00 in the same period last year, primarily from financial product returns[21] - The company has no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[29] - There were no securities investments during the reporting period[30] - The company has not engaged in derivative investments during the reporting period[37] - The company did not conduct any research, communication, or interview activities during the reporting period[38] - There were no violations regarding external guarantees during the reporting period[39]